Clinical Research Directory
Browse clinical research sites, groups, and studies.
Orelabrutinib in the Treatment of HP-positive Gastric MALT Lymphoma
Sponsor: Fudan University
Summary
Describe the efficacy and safety of Orelabrutinib in the treatment of HP-positive gastric MALT lymphoma
Official title: Orelabrutinib in the First-line Treatment of HP-positive Gastric MALT Lymphoma: a Multicenter, Open-label, Randomized Controlled Trial
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
160
Start Date
2024-03
Completion Date
2028-01
Last Updated
2024-02-23
Healthy Volunteers
No
Interventions
Triple therapy for eradication of Helicobacter Pylori and Orelabrutinib
Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break) plus Orelabrutinib for 8 weeks (or until progression, intolerable toxicity, death, or withdrawal from the study)
Triple therapy for eradication of Helicobacter Pylori
Triple therapy for H. pylori (oral administration for 2 weeks, followed by a 1-week break)
Locations (1)
Fudan University Shanghai Cancer Center
Shanghai, Shanghai Municipality, China